LAMEA Transdermal Drug Delivery Systems Market

LAMEA Transdermal Drug Delivery Systems Market Size, Share & Industry Trends Analysis Report By Application (Analgesics, Hormone Replacement Therapies, Hypertension, Motion Sickness, Smoking Cessation), By Type of Delivery System, By Country and Growth Forecast, 2022 - 2028

Report Id: KBV-11639 Publication Date: September-2022 Number of Pages: 76
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Market Report Description

The Latin America, Middle East and Africa Transdermal Drug Delivery Systems Market would witness market growth of 7.7% CAGR during the forecast period (2022-2028).

The medicine is kept in a reservoir that is impermeably covered on one side and has an adhesive that makes contact with the skin on the other in practically all transdermal patch designs. Some designs use medicine that has been dissolved in a fluid or reservoir based on the gel, which can make formulations easier and allow the incorporation of liquid chemical additives like ethanol. These designs typically consist of four layers: an adhesive layer, a semi-permeable layer that may operate as a rate-limiting barrier, a drug reservoir, and an impermeable backing membrane.

Other approaches simplify manufacturing by incorporating the medication into a rigid polymer matrix. By removing the semi-permeable membrane, matrix systems can have just two layers or three layers if the medicine is incorporated into the glue. The need for geriatric medications has greatly increased due to the increase in the worldwide population. Transdermal drug delivery devices aid in the regulated distribution of medications, enhancing the efficacy of geriatric medications. Furthermore, during the past few decades, there has been a marked rise in the number of people with chronic illnesses like arthritis, diabetes, and heart disease.

These chronic conditions are the main source of disability and fatalities worldwide. Due to these issues, more R&D is being done to improve the efficacy of medications. Additionally, people are becoming more informed about how to utilize certain medications. These elements have boosted the market growth for transdermal medication delivery systems.

The Middle East has experienced a sharp rise in wealth over the past ten years, particularly among Gulf Cooperation Council (GCC) nations. This extraordinary gain in income has been accompanied by quick changes in lifestyle that have led to a sharp increase in chronic disease. Over the following decades, the severity of diabetes is anticipated to increase as the Middle East experiences the biggest rise in the incidence of type 2 diabetes, with over 60 million diabetics by 2030. These factors have accelerated the demand for medications in the region which will ultimately establish the transdermal drug delivery systems market in these regions.

The Brazil market dominated the LAMEA Transdermal Drug Delivery Systems Market by Country in 2021; thereby, achieving a market value of $1,256.8 million by 2028. The Argentina market is exhibiting a CAGR of 8.2% during (2022 - 2028). Additionally, The UAE market would experience a CAGR of 7.4% during (2022 - 2028).

Based on Application, the market is segmented into Analgesics, Hormone Replacement Therapies, Hypertension, Motion Sickness, Smoking Cessation and Others. Based on Type of Delivery System, the market is segmented into Passive and Active. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

Free Valuable Insights: The Global Transdermal Drug Delivery Systems Market is Predict to reach $72.4 Billion by 2028, at a CAGR of 4.6%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris Inc., Bayer AG, Boehringer Ingelheim GmbH, Endo International plc, GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Purdue Pharma L.P., Altaris and Hisamitsu Pharmaceutical Co. Inc.

Scope of the Study

Market Segments Covered in the Report:

By Application

  • Analgesics
  • Hormone Replacement Therapies
  • Hypertension
  • Motion Sickness
  • Smoking Cessation
  • Others

By Type of Delivery System

  • Passive
  • Active

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Viatris Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Endo International plc
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Novartis AG
  • Purdue Pharma L.P.
  • Altaris
  • Hisamitsu Pharmaceutical Co. Inc.
Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now


Call: +1(646) 600-5072


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo